| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 542 | 2021 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 389 | 2021 |
| Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort N Néant, G Lingas, Q Le Hingrat, J Ghosn, I Engelmann, Q Lepiller, ... Proceedings of the National Academy of Sciences 118 (8), e2017962118, 2021 | 223 | 2021 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 171 | 2022 |
| Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ... Nature communications 12 (1), 1735, 2021 | 151 | 2021 |
| Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives Q Le Hingrat, B Visseaux, C Laouenan, S Tubiana, L Bouadma, ... Clinical Microbiology and Infection 27 (5), 789. e1-789. e5, 2021 | 68 | 2021 |
| ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19 M Etienne, N Ettalhaoui, AG Everding, M Evers, I Fabre, M Fabre, ... Scientific data 9 (1), 454, 2022 | 51 | 2022 |
| The value of open-source clinical science in pandemic response: lessons from ISARIC A Abbas, SA Abdukahil, NN Abdulkadir, R Abe, L Abel, L Absil, S Acharya, ... The Lancet infectious diseases 21 (12), 1623-1624, 2021 | 40 | 2021 |
| Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial G Lingas, N Néant, A Gaymard, D Belhadi, G Peytavin, M Hites, T Staub, ... Journal of Antimicrobial Chemotherapy 77 (5), 1404-1412, 2022 | 35 | 2022 |
| Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin G Lingas, K Rosenke, D Safronetz, J Guedj PLoS Computational Biology 17 (1), e1008535, 2021 | 34 | 2021 |
| Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates R Marlin, D Desjardins, V Contreras, G Lingas, C Solas, P Roques, ... Nature Communications 13 (1), 5108, 2022 | 26 | 2022 |
| French COVID Cohort Investigators and French Cohort Study groups. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French … N Néant, G Lingas, Q Le Hingrat, J Ghosn, I Engelmann, Q Lepiller, ... Proc. Natl. Acad. Sci. USA 118 (8), e2017962118, 2021 | 21 | 2021 |
| Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat. Commun. 12, 1735 JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ... | 11 | 2021 |
| Association of country income level with the characteristics and outcomes of critically ill patients hospitalized with acute kidney injury and COVID-19 M Wainstein, N Spyrison, D Dai, M Ghadimi, JS Chávez-Iñiguez, ... Kidney international reports 8 (8), 1514-1530, 2023 | 9 | 2023 |
| Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients J Baruch, A Rojek, C Kartsonaki, BKT Vijayaraghavan, BP Gonçalves, ... Influenza and other respiratory viruses 16 (6), 1040-1050, 2022 | 9 | 2022 |
| T cell immunogenicity, gene expression profile, and safety of four heterologous prime-boost combinations of HIV vaccine candidates in healthy volunteers: results of the … L Richert, JD Lelièvre, C Lacabaratz, L Hardel, H Hocini, A Wiedemann, ... The Journal of Immunology 208 (12), 2663-2674, 2022 | 9 | 2022 |
| Survival of SARS-CoV-2 on non-porous materials in an experimental setting representative of fomites L Bonil, G Lingas, D Coupeau, JC Lucet, J Guedj, B Visseaux, B Muylkens Coatings 11 (4), 371, 2021 | 9 | 2021 |
| Favipiravir and severe acute respiratory syndrome coronavirus 2 in hamster model JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ... bioRxiv, 2020.07. 07.191775, 2020 | 7 | 2020 |
| Neutrophil activation and immune thrombosis profiles persist in convalescent COVID-19 H Hocini, A Wiedemann, F Blengio, C Lefebvre, M Cervantes-Gonzalez, ... Journal of Clinical Immunology 43 (5), 882-893, 2023 | 6 | 2023 |
| Neutralizing antibody levels as a correlate of protection against SARS‐CoV‐2 infection: a modeling analysis G Lingas, D Planas, H Péré, F Porrot, F Guivel‐Benhassine, I Staropoli, ... Clinical Pharmacology & Therapeutics 115 (1), 86-94, 2024 | 5 | 2024 |
